Recombinant Human Interleukin-2 Injection (Beijing Four Rings Biopharmaceutical)

重组人白介素-2注射液 (北京四环生物制药有限公司)

Report date: 2022/02/17 16:28:58

Base Information

Drug NameRecombinant Human Interleukin-2 Injection (Beijing Four Rings Biopharmaceutical)
Drug Alias NameNew De Lusheng新德路生
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterleukin-2 receptor agonists
TargetsInterleukin-2 receptor
Therapy Area/IndicationsThrombocytopenia
Global Approved IndicationsThrombocytopenia
Approved Indications in ChinaThrombocytopenia
Original Approved Country/TerritoryMainland China
Original Approved Date1997/01/01
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsThrombocytopenia
Inactive IndicationsN/A

Other Information

ATC CodeL03AC01
Related LinksN/A